Backgound: Serum 1,5-anhydroglucitol (1,5-AG) is a known marker reflecting recent glycaemic control. In this study, we examined serum 1,5-AG levels in chronic liver disease (CLD) patients with and without diabetes mellitus. Methods: Eighty patients with CLD were compared with 667 subjects without CLD. Glycaemic control of the CLD patients was evaluated by estimated glycated haemoglobin (HbA 1C ) calculated using the equation by Rohlfing et al. from mean plasma glucose because CLD patients have apparently low HbA 1C .Results: When the study participants were divided into subgroups stratified by HbA 1C levels, the CLD patients whose estimated HbA 1C levels were less than 7.0% showed significantly lower 1,5-AG than their counterparts of the control subjects.Stepwise multivariable analysis revealed that estimated HbA 1C was the significant explanatory variable for 1,5-AG in the CLD patients. However, in the CLD patients with estimated HbA 1C less than 5.8%, only hepaplastin test was the significant explanatory variable for 1,5-AG. Conclusions: Serum 1,5-AG levels are low irrespective of plasma glucose levels in the CLD patients with and without diabetes. The CLD patients who had low serum 1,5-AG levels were associated with deteriorated liver function.